PreprintArticleVersion 2Preserved in Portico This version is not peer-reviewed
A New Set-up of Vanishing Antibodies: A Biennial Follow-up of Five Different Clients’ Humoral Responses Against Sars-Cov-2 After Systemic Vaccination in an Oncology Hospital in Poland
Version 1
: Received: 5 October 2022 / Approved: 6 October 2022 / Online: 6 October 2022 (08:42:11 CEST)
Version 2
: Received: 29 November 2022 / Approved: 1 December 2022 / Online: 1 December 2022 (10:22:30 CET)
Kosiorek, P.; Stróż, S.; Hryniewicz, A.; Kazberuk, D.E.; Milewski, R.; Bartoszewicz, K.; Borkowska, M.J.; Stasiak‐Barmuta, A. A New Set‐up of Vanishing Antibodies: A Biennial Follow‐up of Five Different Clients’ Humoral Responses against SARS‐CoV‐2 after Systemic Vaccination in an Oncology Hospital in Poland. Health Science Reports 2023, 6, doi:10.1002/hsr2.1172.
Kosiorek, P.; Stróż, S.; Hryniewicz, A.; Kazberuk, D.E.; Milewski, R.; Bartoszewicz, K.; Borkowska, M.J.; Stasiak‐Barmuta, A. A New Set‐up of Vanishing Antibodies: A Biennial Follow‐up of Five Different Clients’ Humoral Responses against SARS‐CoV‐2 after Systemic Vaccination in an Oncology Hospital in Poland. Health Science Reports 2023, 6, doi:10.1002/hsr2.1172.
Kosiorek, P.; Stróż, S.; Hryniewicz, A.; Kazberuk, D.E.; Milewski, R.; Bartoszewicz, K.; Borkowska, M.J.; Stasiak‐Barmuta, A. A New Set‐up of Vanishing Antibodies: A Biennial Follow‐up of Five Different Clients’ Humoral Responses against SARS‐CoV‐2 after Systemic Vaccination in an Oncology Hospital in Poland. Health Science Reports 2023, 6, doi:10.1002/hsr2.1172.
Kosiorek, P.; Stróż, S.; Hryniewicz, A.; Kazberuk, D.E.; Milewski, R.; Bartoszewicz, K.; Borkowska, M.J.; Stasiak‐Barmuta, A. A New Set‐up of Vanishing Antibodies: A Biennial Follow‐up of Five Different Clients’ Humoral Responses against SARS‐CoV‐2 after Systemic Vaccination in an Oncology Hospital in Poland. Health Science Reports 2023, 6, doi:10.1002/hsr2.1172.
Abstract
The humoral response of the COVID-19 vaccine varies from person to person. It largely depends on prior SARS-CoV-2 infection, obtaining an adequate immune response, and leaving a trace of changing antibody concentration over time. We retrospectively analyzed five clinical cases from selected patients and employees of the oncology hospital. All mild COVID-19 convalescents received the BNT162b2-Comirnaty mRNA vaccine three or four times. The levels of SARS-CoV-2 IgM- and IgG-specific antibodies, as well as S-RBD antibodies, were analyzed for two years. The concentration of antibodies was assessed in the laboratory using the chemiluminescent immunoassay CLIA, MAGLUMI. Results: (1) Active autoimmune disease stabilized the level of IgG-specific antibodies after systemic mRNA vaccination for at least six months. (2) Post-vaccination IgG and S-RBD levels decreased when vaccination was performed within three months of onset. (3) The booster dose administered only increased the S-RBD antibody levels. Declining IgG-specific antibodies were observed. (4) The S-RBD IgG levels were not correlated with the SARS-CoV-2 IgG levels in the vaccinated convalescents. (5) Subsequent reinfection with SARS-CoV-2 after vaccination three times released a more significant specific antibody response. Based on the collected data, we suggest that monitoring S-RBD antibodies is sensitive but not equivalent to a specific humoral response for SARS-CoV-2 IgG. We suggested that administering at least three doses of the mRNA vaccine should serve as the basis for immunization. The three-month interval may be the best alternative to an immunization schedule for non-immunocompromised people.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
1 December 2022
Commenter:
Piotr Kosiorek
Commenter's Conflict of Interests:
Author
Comment: A new set-up of vanishing antibodies: A biennial follow-up of five different clients' humoral responses against SARS-CoV-2 after systemic vaccination in an oncology hospital in Poland
(Request from editors to extend to 5 cases in 2 years follow-up vaccination and COVID-19 disease)
Commenter: Piotr Kosiorek
Commenter's Conflict of Interests: Author
(Request from editors to extend to 5 cases in 2 years follow-up vaccination and COVID-19 disease)